Abstract:The inflammatory mechanism of chronic sinusitis with nasal polyp type (CRSwNP) is complex, and existing treatments are ineffective in controlling the disease. Omalizumab reduces the immune cascade by binding to IgE receptors in patients with CRSwNP. Omalizumab has been proved to be effective in alleviating nasal symptoms in patients with asthma complicated with CRSwNP. However, the efficacy of omalizumab in refractory relapsing CRSwNP with eosinophilia and high IgE levels needs to be demonstrated in more and larger randomized controlled trials. In this paper, the application and the mechanism of omalizumab in patients with CRSwNP with asthma, which was described in combination with this background, so as to provide reference for the treatment of CRSwNP.
